1Department of Neurology, Daping Hospital, Third Military Medical University, Chongqing 400042, China 
2State Key Laboratory of Trauma, Burn and Combined Injury, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing 400042, China

Abstract 

Alzheimer’s disease (AD), the most common type of dementia, is becoming a major challenge for global health and social care. However, the current understanding of AD pathogenesis is limited, and no early diagnosis and disease-modifying therapy are currently available. During the past year, significant progress has been made in clinical research on the diagnosis, prevention, and treatment of AD. In this review, we summarize the latest achievements, including diagnostic biomarkers, polygenic hazard score, amyloid and tau PET imaging, clinical trials targeting amyloid-beta (Aβ), tau, and neurotransmitters, early intervention, and primary prevention and systemic intervention approaches, and provide novel perspectives for further efforts to understand and cure the disease.

Keywords

Alzheimer’s disease; Amyloid-beta; Tau; Immunotherapy; BACE1 inhibitor; 5-HT6 receptor antagonist; Primary prevention; Positron emission tomographic imaging; Biomarker

[SpringerLink]